<scp>MiR</scp> ‐126‐3p and <scp>MiR</scp> ‐195‐5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the <scp>IRS1</scp> / <scp>PI3K</scp> Signalling Pathway
Our results unravel that miR-126 and miR-195 inhibit liver fibrosis by suppressing the IRS/PI3K pathway.
Authors
- Jie Li (ORCID: https://orcid.org/0000-0002-3069-4969)
- Hongting Li
- Peng Lyu
- Kun Zhang (ORCID: https://orcid.org/0000-0001-5891-0400)
- Kang Zhang (ORCID: https://orcid.org/0000-0002-4549-1697)
- Bo Liu (ORCID: https://orcid.org/0000-0003-4526-714X)
- Xia Yuan (ORCID: https://orcid.org/0000-0002-0422-6475)
- Liping Ma
- Xuemei Zhao
- Dan Wang (ORCID: https://orcid.org/0000-0001-7974-1749)
Institutions
- China National Nuclear Corporation (CN)
- Chengdu Medical College (CN)
- Third People's Hospital of Chengdu (CN)
- First Affiliated Hospital of Chengdu Medical College (CN)
- Chengdu Second People's Hospital (CN)
Publication Details
- Journal
- Liver International
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/liv.70302
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- National Natural Science Foundation of China